- Home
- INM
as 10-24-2025 3:56pm EST
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
| Founded: | 1981 | Country: | Canada |
| Employees: | N/A | City: | VANCOUVER |
| Market Cap: | 5.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 116.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.72 - $8.27 | Next Earning Date: | 11-13-2025 |
| Revenue: | $4,942,633 | Revenue Growth: | 7.50% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest InMed Pharmaceuticals Inc. News
INM Breaking Stock News: Dive into INM Ticker-Specific Updates for Smart Investing
Newsfile
11 days ago
InMed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors
Newsfile
18 days ago
InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors
Newsfile
4 months ago
InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules
Newsfile
4 months ago
InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
MT Newswires
4 months ago
InMed Says Preclinical Data Show INM-901 'Significantly' Reduces Neuroinflammation; Shares Jump
MT Newswires
4 months ago
Top Premarket Gainers
Newsfile
4 months ago
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
Newsfile
4 months ago
InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA
Compare INM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INM InMed Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.